Trials / Completed
CompletedNCT00680680
Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker
Phase 4 Study of Dual Five Alpha Reductase Inhibition Combined With Alpha Blockade in Men With Refractory Urinary Retention Secondary to BPH
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Franklin D. Gaylis, MD Inc. · Academic / Other
- Sex
- Male
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter. Following treatment with an Alpha Blocker alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride | Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2008-05-20
- Last updated
- 2008-05-20
Source: ClinicalTrials.gov record NCT00680680. Inclusion in this directory is not an endorsement.